Hu M, Fan J Y, Zhou X, Cao G W, Tan Xiaojie
Department of Epidemiology, Faculty of Naval Medicine, Naval Medical University, Shanghai 200433, China.
Zhonghua Liu Xing Bing Xue Za Zhi. 2023 Apr 10;44(4):575-580. doi: 10.3760/cma.j.cn112338-20220624-00558.
To analyze the global epidemiology of renal cell carcinoma (RCC) in 2020. The incidence and mortality data of RCC in the cooperative database GLOBOCAN 2020 of International Agency for Research on Cancer of WHO and the human development index (HDI) published by the United Nations Development Programme in 2020 were collated. The crude incidence rate (CIR), age-standardized incidence rate (ASIR), crude mortality rate (CMR), age-standardized mortality rate (ASMR) and mortality/incidence ratio (M/I) of RCC were calculated. Kruskale-Wallis test was used to analyze the differences in ASIR or ASMR among HDI countries. In 2020, the global ASIR of RCC was 4.6/100 000, of which 6.1/100 000 for males and 3.2/100 000 for females and ASIR was higher in very high and high HDI countries than that in medium and low HDI countries. With the rapid increase of age after the age of 20, the growth rate of ASIR in males was faster than that in females, and slowed down at the age of 70 to 75. The truncation incidence rate of 35-64 years old was 7.5/100 000 and the cumulative incidence risk of 0-74 years old was 0.52%. The global ASMR of RCC was 1.8/100 000, 2.5/100 000 for males and 1.2/100 000 for females. The ASMR of males in very high and high HDI countries (2.4/100 000-3.7/100 000) was about twice that of males (1.1/100 000-1.4/100 000) in medium and low HDI countries, while the ASMR of female (0.6/100 000-1.5/100 000) did not show significant difference. ASMR continued to increase rapidly with age after the age of 40, and the growth rate of males was faster than that of females. The truncation mortality rate of 35-64 years old was 2.1/100 000, and the cumulative mortality risk of 0-74 years old was 0.20%. M/I decreases with the increase of HDI, with M/I as 0.58 in China, which was higher than the global average of 0.39 and the United States' 0.17. The ASIR and ASMR of RCC presented significant regional and gender disparities globally, and the heaviest burden was in very high HDI countries.
分析2020年全球肾细胞癌（RCC）的流行病学情况。整理了世界卫生组织国际癌症研究机构的合作数据库GLOBOCAN 2020中RCC的发病率和死亡率数据以及联合国开发计划署2020年发布的人类发展指数（HDI）。计算了RCC的粗发病率（CIR）、年龄标准化发病率（ASIR）、粗死亡率（CMR）、年龄标准化死亡率（ASMR）和死亡率/发病率比（M/I）。采用Kruskal-Wallis检验分析HDI国家间ASIR或ASMR的差异。2020年，全球RCC的ASIR为4.6/10万，其中男性为6.1/10万，女性为3.2/10万，极高和高HDI国家的ASIR高于中低HDI国家。20岁后随着年龄快速增长，男性ASIR的增长速度快于女性，并在70至75岁时放缓。35至64岁的截缩发病率为7.5/10万，0至74岁的累积发病风险为0.52%。全球RCC的ASMR为1.8/10万，男性为2.5/10万，女性为1.2/10万。极高和高HDI国家男性的ASMR（2.4/10万 - 3.7/10万）约为中低HDI国家男性（1.1/10万 - 1.4/10万）的两倍，而女性的ASMR（0.6/10万 - 1.5/10万）未显示出显著差异。40岁后ASMR随年龄继续快速上升，男性的增长速度快于女性。35至64岁的截缩死亡率为2.1/10万，0至74岁的累积死亡风险为0.20%。M/I随HDI升高而降低，中国的M/I为0.58，高于全球平均水平0.39和美国的0.17。全球RCC的ASIR和ASMR存在显著的地区和性别差异，负担最重的是极高HDI国家。
